
Jeffrey H Teckman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4727198/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Degradation of a Mutant Secretory Protein, α1-Antitrypsin Z, in the Endoplasmic Reticulum Requires Proteasome Activity. Journal of Biological Chemistry, 1996, 271, 22791-22795.	3.4	331
2	Retention of mutant α ₁ -antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. American Journal of Physiology - Renal Physiology, 2000, 279, G961-G974.	3.4	244
3	Obese children with steatohepatitis can develop cirrhosis in childhood. American Journal of Gastroenterology, 2002, 97, 2460-2462.	0.4	224
4	α1-Antitrypsin deficiency. Nature Reviews Disease Primers, 2016, 2, 16051.	30.5	215
5	Mitochondrial autophagy and injury in the liver in ${\rm \hat{l}\pm1}$ -antitrypsin deficiency. American Journal of Physiology - Renal Physiology, 2004, 286, G851-G862.	3.4	183
6	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 668-682.	0.7	148
7	A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with α ₁ -antitrypsin deficiency. Hepatology, 2010, 52, 1078-1088.	7.3	138
8	Defining the mechanism of polymerization in the serpinopathies. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17146-17151.	7.1	135
9	Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alphaâ€1â€antiâ€trypsin deficiency. EMBO Molecular Medicine, 2013, 5, 397-412.	6.9	134
10	Molecular pathogenesis of liver disease in ?1-antitrypsin deficiency. Hepatology, 1996, 24, 1504-1516.	7.3	133
11	The Proteasome Participates in Degradation of Mutant α1-Antitrypsin Z in the Endoplasmic Reticulum of Hepatoma-derived Hepatocytes. Journal of Biological Chemistry, 2001, 276, 44865-44872.	3.4	124
12	Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency. Hepatology, 2004, 39, 1048-1055.	7.3	122
13	Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Experimental Biology and Medicine, 2010, 235, 700-709.	2.4	110
14	Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles. Molecular Therapy, 2012, 20, 590-600.	8.2	105
15	Lack of Effect of Oral 4-Phenylbutyrate on Serum Alpha-1-Antitrypsin in Patients with α-1-Antitrypsin Deficiency: A Preliminary Study. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 34-37.	1.8	97
16	Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology, 2007, 46, 1228-1235.	7.3	91
17	Fasting in α ₁ -antitrypsin deficient liver: constitutive activation of autophagy. American Journal of Physiology - Renal Physiology, 2002, 283, G1156-G1165.	3.4	80
18	The Endoplasmic Reticulum Degradation Pathway for Mutant Secretory Proteins α1-Antitrypsin Z and S Is Distinct from That for an Unassembled Membrane Protein. Journal of Biological Chemistry, 1996, 271, 13215-13220.	3.4	78

#	Article	IF	CITATIONS
19	Diagnosis and Management of Patients With α1-Antitrypsin (A1AT) Deficiency. Clinical Gastroenterology and Hepatology, 2012, 10, 575-580.	4.4	76
20	Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 35-43.	1.6	71
21	Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin–related liver disease in mice. Journal of Clinical Investigation, 2014, 124, 251-261.	8.2	70
22	A Naturally Occurring Nonpolymerogenic Mutant of $\hat{l}\pm 1$ -Antitrypsin Characterized by Prolonged Retention in the Endoplasmic Reticulum. Journal of Biological Chemistry, 2001, 276, 33893-33898.	3.4	60
23	Quantitative isolation of ?1AT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology, 2005, 41, 160-167.	7.3	58
24	Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions. Mutation Research - Reviews in Mutation Research, 2017, 773, 14-25.	5.5	58
25	In vivo post-transcriptional gene silencing of $\hat{l}\pm$ -1 antitrypsin by adeno-associated virus vectors expressing siRNA. Laboratory Investigation, 2007, 87, 893-902.	3.7	57
26	Role of ubiquitin in proteasomal degradation of mutant α ₁ -antitrypsin Z in the endoplasmic reticulum. American Journal of Physiology - Renal Physiology, 2000, 278, G39-G48.	3.4	55
27	Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology, 2006, 44, 976-982.	7.3	55
28	Determination of hepatitis B phenotype using biochemical andÂserological markers. Journal of Viral Hepatitis, 2017, 24, 320-329.	2.0	55
29	Alpha-1-Antitrypsin Deficiency Liver Disease. Clinics in Liver Disease, 2018, 22, 643-655.	2.1	54
30	Oxidative stress contributes to liver damage in a murine model of alpha-1-antitrypsin deficiency. Experimental Biology and Medicine, 2012, 237, 1163-1172.	2.4	51
31	Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice. Human Gene Therapy, 2018, 29, 861-873.	2.7	49
32	α ₁ -Antitrypsin Deficiency in Childhood. Seminars in Liver Disease, 2007, 27, 274-281.	3.6	47
33	Combination of Entecavir/Peginterferon Alfaâ€2a in Children With Hepatitis B e Antigen–Positive Immune Tolerant Chronic Hepatitis B Virus Infection. Hepatology, 2019, 69, 2326-2337.	7.3	45
34	Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Review of Gastroenterology and Hepatology, 2015, 9, 261-268.	3.0	44
35	Corneal opacities associated with NTBC treatment. American Journal of Ophthalmology, 2002, 134, 266-268.	3.3	41
36	Baseline Analysis of a Young αâ€1â€Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, 94-101.	1.8	41

#	Article	IF	CITATIONS
37	Activating Transcription Factor 6 Limits Intracellular Accumulation of Mutant α1-Antitrypsin Z and Mitochondrial Damage in Hepatoma Cells. Journal of Biological Chemistry, 2011, 286, 41563-41577.	3.4	40
38	Neurodevelopmental Outcome of Young Children with Biliary Atresia and Native Liver: Results from the ChiLDReN Study. Journal of Pediatrics, 2018, 196, 139-147.e3.	1.8	40
39	REVIEW: α ₁ â€Antitrypsin deficiency associated liver disease. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 404-416.	2.8	39
40	Characteristics of hepatocellular carcinoma in a murine model of alphaâ€1â€antitrypsin deficiency. Hepatology Research, 2010, 40, 641-653.	3.4	38
41	Alpha-1-antitrypsin deficiency: Diagnosis, pathophysiology, and management. Current Gastroenterology Reports, 2006, 8, 14-20.	2.5	37
42	Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight, 2020, 5, .	5.0	37
43	Sustained Knockdown of a Disease-Causing Gene in Patient-Specific Induced Pluripotent Stem Cells Using Lentiviral Vector-Based Gene Therapy. Stem Cells Translational Medicine, 2013, 2, 641-654.	3.3	36
44	The Serpinopathies. Methods in Enzymology, 2011, 501, 421-466.	1.0	35
45	Advances in Alpha-1-Antitrypsin Deficiency Liver Disease. Current Gastroenterology Reports, 2014, 16, 367.	2.5	32
46	Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis. Hepatology, 2019, 69, 245-257.	7.3	31
47	α1-Antitrypsin Deficiency: From Genotype to Childhood Disease. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 65-74.	1.8	30
48	Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology, 1996, 24, 1504-1516.	7.3	29
49	Children with Chronic Hepatitis B in the United States and Canada. Journal of Pediatrics, 2015, 167, 1287-1294.e2.	1.8	28
50	Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease. American Journal of Physiology - Renal Physiology, 2016, 311, G156-G165.	3.4	27
51	NorUDCA promotes degradation of $\hat{1}\pm 1$ -antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. PLoS ONE, 2018, 13, e0200897.	2.5	27
52	Conceptual advances in the pathogenesis and treatment of childhood metabolic liver disease. Gastroenterology, 1995, 108, 1263-1279.	1.3	25
53	Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome. Journal of Pediatrics, 2015, 167, 390-396.e3.	1.8	25
54	Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1â€antitrypsin. Hepatology, 2017, 65, 1319-1335.	7.3	25

#	Article	IF	CITATIONS
55	Pathophysiology of Alpha-1 Antitrypsin Deficiency Liver Disease. Methods in Molecular Biology, 2017, 1639, 1-8.	0.9	25
56	Hepatic Progenitor Cell Proliferation and Liver Injury in αâ€1â€Antitrypsin Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 626-630.	1.8	24
57	Total Serum Bilirubin Predicts Fatâ€Soluble Vitamin Deficiency Better Than Serum Bile Acids in Infants With Biliary Atresia. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 702-707.	1.8	24
58	Activation of the câ€Jun Nâ€ŧerminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1â€antitrypsin. Hepatology, 2017, 65, 1865-1874.	7.3	24
59	Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Review of Gastroenterology and Hepatology, 2018, 12, 853-862.	3.0	24
60	Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology. Children, 2015, 2, 358-370.	1.5	23
61	Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid–Treated Animals Receiving Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2017, 41, 198-207.	2.6	22
62	Oleanolic Acid Improves Gut Atrophy Induced by Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2016, 40, 67-72.	2.6	21
63	Appropriateness of Newborn Screening for α1â€Antitrypsin Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 199-203.	1.8	20
64	Alpha-1 antitrypsin deficiency liver disease. Translational Gastroenterology and Hepatology, 2021, 6, 23-23.	3.0	20
65	Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet Journal of Rare Diseases, 2020, 15, 96.	2.7	18
66	Review of Gastrointestinal Motility in Cystic Fibrosis. Journal of Cystic Fibrosis, 2021, 20, 578-585.	0.7	18
67	CHOP and c-JUN up-regulate the mutant Z α1-antitrypsin, exacerbating its aggregation and liver proteotoxicity. Journal of Biological Chemistry, 2020, 295, 13213-13223.	3.4	16
68	Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
69	Validating hyperbilirubinemia and gut mucosal atrophy with a novel ultramobile ambulatory total parenteral nutrition piglet model. Nutrition Research, 2015, 35, 169-174.	2.9	15
70	Pediatric Intestinal Failure Review. Children, 2018, 5, 100.	1.5	14
71	Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 588-594.	1.8	13
72	Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada. Journal of Pediatrics, 2021, 237, 24-33.e12.	1.8	10

#	Article	IF	CITATIONS
73	Emerging Concepts and Human Trials in Alpha-1-Antitrypsin Deficiency Liver Disease. Seminars in Liver Disease, 2017, 37, 152-158.	3.6	9
74	Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with Native Liver Reveal that Neonatal Cholestasis is a Poor Predictor of Future Portal Hypertension. Journal of Pediatrics, 2020, 227, 81-86.e4.	1.8	9
75	Diagnostic accuracy of non-contrast magnetic resonance enterography in detecting active bowel inflammation in pediatric patients with diagnosed or suspected inflammatory bowel disease to determine necessity of gadolinium-based contrast agents. Pediatric Radiology, 2019, 49, 759-769.	2.0	8
76	Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?. Therapeutic Advances in Chronic Disease, 2021, 12_suppl, 204062232199568.	2.5	8
77	279 Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency. Gastroenterology, 2015, 148, S-975.	1.3	7
78	AFM Imaging Reveals Topographic Diversity of Wild Type and Z Variant Polymers of Human α1-Proteinase Inhibitor. PLoS ONE, 2016, 11, e0151902.	2.5	7
79	Healthâ€related Quality of Life in Pediatric Patients With Chronic Hepatitis B Living in the United States and Canada. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 760-769.	1.8	7
80	Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 177-190.	0.7	7
81	Changes in serum hepatitis B surface and e antigen, interferonâ€inducible protein 10, and aminotransferase levels during combination therapy of immuneâ€tolerant chronic hepatitis B. Hepatology, 2022, 76, 775-787.	7.3	7
82	Alpha-1 Antitrypsin Deficiency Liver Disease. Clinics in Liver Disease, 2022, 26, 391-402.	2.1	7
83	PiZ Mouse Liver Accumulates Polyubiquitin Conjugates That Associate with Catalytically Active 26S Proteasomes. PLoS ONE, 2014, 9, e106371.	2.5	6
84	Hepatic Histology in Treatmentâ€naÃ⁻ve Children With Chronic Hepatitis B Infection Living in the United States and Canada. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 99-105.	1.8	6
85	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. Journal of Viral Hepatitis, 2021, 28, 1526-1538.	2.0	6
86	Clinical significance of quantitative e antigen in a cohort of hepatitis B virusâ€infected children and adults in North America. Journal of Viral Hepatitis, 2021, 28, 1042-1056.	2.0	5
87	Author's Response. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, e38.	1.8	4
88	Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 224-246.	0.7	4
89	Semiquantitation of Monomer and Polymer Alpha-1 Antitrypsin by Centrifugal Separation and Assay by Western Blot of Soluble and Insoluble Components. Methods in Molecular Biology, 2017, 1639, 227-234.	0.9	3
90	Alpha-1- Antitrypsin Deficiency Liver Disease: Science and Therapeutic Potential 50 Years Later. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, .	0.2	3

#	Article	IF	CITATIONS
91	Liver Disease Due to Alphaâ€1 Antitrypsin Deficiency: Are We Surprised That It Is More Complex Than We Thought?. Hepatology, 2019, 70, 5-7.	7.3	2
92	Clinical approach to paediatric liver disease. , 2019, , 105-113.		2
93	Alphaâ€lâ€Antitrypsin Deficiency. Clinical Liver Disease, 2022, 19, 89-92.	2.1	2
94	593 Antisense Oligonucleotide Reduction of Mutant Alpha-1 Antitrypsin Protein for the Treatment of Alpha-1 Antitrypsin Liver Disease. Gastroenterology, 2012, 142, S-919.	1.3	1
95	Review of Treatment Outcomes in Pediatric Patients with Concomitant Eosinophilic Esophagitis and Celiac Disease. Journal of Allergy and Clinical Immunology, 2013, 131, AB181.	2.9	1
96	Author's Response. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, e26.	1.8	1
97	Alpha-1-Antitrypsin Deficiency Liver Disease. , 2017, , 117-131.		1
98	Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy. Pediatric Transplantation, 2021, , e14164.	1.0	1
99	Hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Gastroenterology, 2003, 124, A713.	1.3	Ο
100	Isolation of alpha-1-antitrypsin mutant Z protein polymers from liver and their role in cellular injury. Gastroenterology, 2003, 124, A689.	1.3	0
101	Selected Summary. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 115-116.	1.8	0
102	Pro-Inflammatory Consequences Of Human Z Protein After Cigarette Smoke Exposure. , 2011, , .		0
103	702 Baseline Analysis of the Largest Reported Cohort of Children and Young Adults With Alpha-1-Antitrypsin Deficiency Liver Disease Reveals a Significant Burden of Portal Hypertension Without Jaundice. Gastroenterology, 2012, 142, S-924.	1.3	Ο
104	850c RNAi Therapeutics Ameliorate Liver Disease Associated with Alpha-1-Antitrypsin Deficiency. Gastroenterology, 2014, 146, S-145.	1.3	0
105	Tu1127 Health-Related Quality of Life in a Cohort of Children With Chronic Hepatitis B. Gastroenterology, 2014, 146, S-761.	1.3	Ο
106	Mo1679 Development and Validation of a Novel Ultra-Mobile Ambulatory Total Parenteral Nutrition Model. Gastroenterology, 2014, 146, S-634.	1.3	0
107	Su1004 Drug Resistance, Basal Core Promoter and Pre-Core Stop Mutations in a Large Cohort of North American Children With Hepatitis B: Results for the Pediatric Cohort Study of the NIDDK-Sponsored Hepatitis B Research Network (HBRN). Gastroenterology, 2014, 146, S-960.	1.3	Ο
108	Su1798 Glucagon-Like Peptides Ameliorate Total Prenteral Nutrition Associated Gut Atrophy. Gastroenterology, 2015, 148, S-1054.	1.3	0

#	Article	IF	CITATIONS
109	808 HBeAg(+) Immune Tolerant Phenotype Is Rare Among Children In The Largest US-Canadian Cohort With Chronic HBV Infection. Gastroenterology, 2016, 150, S1048.	1.3	0
110	940 Death Is Rare and Progression to Transplant Is Slow, Despite a Burden of Portal Hypertension, in Longitudinal Outcomes of Alpha-1-Antitrypsin Deficiency From the Children Cohort. Gastroenterology, 2016, 150, S1052-S1053.	1.3	0
111	Quantitative Surface Antigen and E Antigen in Children with Chronic Hepatitis B: Results from the Pediatric Cohort Study of the Niddk-Sponsored Hepatitis B Research Network (HBRN). Gastroenterology, 2017, 152, S1071-S1072.	1.3	0
112	Alpha-1 Antitrypsin Deficiency: Cytotoxic Z Polymer Formation in the Lungs Promotes Increased Apoptosis. , 2020, , .		0
113	Alpha-1-Antitrypsin (α1AT) Deficiency, Pediatric. , 2004, , 48-51.		0
114	Alpha-1-Antitrypsin Deficiency and Mechanisms of Liver Disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 289-298.	1.1	0
115	Alpha-1-Antitrypsin Deficiency Liver Disease and New Treatment Opportunities. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 1970, 10, 382-391.	1.1	0
116	Innovations in Pediatrics: 2019. Missouri Medicine, 2019, 116, 105.	0.3	0